BACKGROUND: About 2-11% of all patients (pts) with RCC develop BM, leading to a poor prognosis and a median survival of ,6 months after whole brain radiotherapy. This study was designed to evaluate targeted therapy in RCC pts with BM. METHODS: Eligible pts had confirmed RCC and BM (≥1 lesion of ≥10mm diameter) aged .18 years with ECOG performanse status (PS) of 0-2. From
BM were enrolled in this study. 14 pts (87,5%) had extracranial metastases. 9 pts received sunitinib, 6 pts received sorafenib and 1 patient received pazopanib until radiologically-verified progressive disease. The primary endpoints were objective response rate (ORR) in the brain and in the extracranial lesions, progressive-free survival (PFS) and overall survival. Previous treatment: nephrectomy -14 pts (87,5%), cytokines -9 pts (56,3%), targeted therapy (before BM) -4 pts (37,5%). Local control of BM: previous neurosurgery -3 pts (18,8%), radiosurgery -6 pts (37,5%), previous neurosurgery + radiosurgery -3 pts (18,8%). RESULTS: ORR in the brain was 31,3% (5 partial responses). All partial responses in the brain achieved in patients who received targeted therapy and radiosurgery. Stable disease in the brain was 50,0% (8 pts). 1 patient with stable in the brain received targeted therapy and radiosurgery, 7 pts received targeted therapy. ORR in the extracranial lesions was 25,0% (4 partial responses). Stable disease in the extracranial lesions was 50% (8 pts). The median of PFS was 6 months. The median of overall survival was 10 months. CONCLUSIONS: Surgery and radiotherapy, including radiosurgery, must be considered as optimal local treatment for pts with RCC and BM. Targeted drugs have demonstrated their ability to achifve a clinical and X-ray verified objective effect (as stabilization in most cases) in treating of pts with disseminated RCC and BM.
